Citigroup upgraded it rating on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to Buy from Neutral after its survey of retinal surgeons indicated the company’s Eylea drug will beat estimates over the near and long term. Citi also believes Regeneron’s pipeline is not adequately reflected in the current share price. The firm raised its price target for the stock to $390 from $342. Shares of Regeneron (REGN) closed … Continue reading Stocks Moving After-Hours: Regeneron Pharmaceuticals Inc (NASDAQ:REGN), Kinder Morgan Management (NYSE:KMR), FutureFuel (NYSE:FF)